Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Irma M, Oving"'
Autor:
Marieke Pape, Pauline A. J. Vissers, Willemieke P. M. Dijksterhuis, David Bertwistle, Laura McDonald, Bianca Mostert, Sarah Derks, Irma M. Oving, Rob H. A. Verhoeven, Hanneke W. M. van Laarhoven
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: Treatment of advanced or metastatic esophageal adenocarcinoma (EAC) follows the guidelines for gastroesophageal junction adenocarcinoma (GEJC) and gastric adenocarcinoma (GAC), but patients with EAC are often excluded from clinical studie
Externí odkaz:
https://doaj.org/article/da8a32e3e4c643658b983aa7f4de6aaa
Autor:
Emmy Boerrigter, Guillemette E. Benoist, Inge M. vanOort, Gerald W. Verhaegh, Onno vanHooij, Levi Groen, Frank Smit, Irma M. Oving, Pieter deMol, Tineke J. Smilde, Diederik M. Somford, Niven Mehra, Jack A. Schalken, Nielka P. vanErp
Publikováno v:
Molecular Oncology, Vol 15, Iss 9, Pp 2453-2465 (2021)
Circulating RNAs extracted from liquid biopsies represent a promising source of cancer‐ and therapy‐related biomarkers. We screened whole blood from patients with metastatic castration‐resistant prostate cancer (mCRPC) following their first‐l
Externí odkaz:
https://doaj.org/article/fb1953ab5356432393af69c51aeab14a
Autor:
Maarten J. van der Doelen, Irma M. Oving, Dirk N. J. Wyndaele, Jean-Paul van Basten, Frederiek Terheggen, Addy C. M. van de Luijtgaarden, Wim. J. G. Oyen, W. Dick van Schelven, Franchette van den Berkmortel, Niven Mehra, Marcel J. R. Janssen, Judith B. Prins, Winald R. Gerritsen, José A. E. Custers, Inge M. van Oort
Publikováno v:
Prostate Cancer and Prostatic Diseases, 26, 1, pp. 142-150
Background Radium-223 is a registered treatment option for symptomatic bone metastatic castration-resistant prostate cancer (mCRPC). Aim of this multicenter, prospective observational cohort study was to evaluate health-related quality of life (HR-Qo
Autor:
Michiel Sedelaar, Jochem R.N. van der Voort van Zyp, Jeroen Kneppers, Sjoerd O. Klaver, Jeroen van Moorselaar, Niven Mehra, Stijn W.T.P.J. Heijmink, Herman Stoevelaar, Shafak S Aluwini, Wouter V. Vogel, Martijn P. Lolkema, Tom van der Hulle, James Nagaraj, Tom W. J. Scheenen, Guido Jenster, Hans M. Westgeest, Jules Lavalaye, Ivo G. Schoots, Eva E. Schaake, Inge M. van Oort, Daniela E. Oprea-Lager, Gisele H. J. M. Leyten, Irma M. Oving, Pim J. van Leeuwen, Luc M.F. Moonen, Theo M. de Reijke, Derya Yakar, Igle-Jan de Jong, Martijn B. Busstra, Kim de Vries, Henk G. van der Poel, Walter Noordzij, Susanne Osanto, Diederik M. Somford, Franchette W P J van den Berkmortel
Publikováno v:
European Urology Oncology, 3(2), 231-238. Elsevier BV
European Urology Oncology, 3, 2, pp. 231-238
European Urology Oncology, 3(2), 231
European urology oncology, 3(2), 231-238. Elsevier BV
European Urology Oncology, 3, 231-238
European urology oncology, 3(2), 231-238. De Tijdstroom/Elsevier
Aluwini, S S, Mehra, N, Lolkema, M P, Oprea-Lager, D E, Yakar, D, Stoevelaar, H, van der Poel, H & Dutch Oligometastatic Prostate Cancer Working Group 2020, ' Oligometastatic Prostate Cancer: Results of a Dutch Multidisciplinary Consensus Meeting ', European Urology Oncology, vol. 3, no. 2, pp. 231-238 . https://doi.org/10.1016/j.euo.2019.07.010
European Urology Oncology, 3, 2, pp. 231-238
European Urology Oncology, 3(2), 231
European urology oncology, 3(2), 231-238. Elsevier BV
European Urology Oncology, 3, 231-238
European urology oncology, 3(2), 231-238. De Tijdstroom/Elsevier
Aluwini, S S, Mehra, N, Lolkema, M P, Oprea-Lager, D E, Yakar, D, Stoevelaar, H, van der Poel, H & Dutch Oligometastatic Prostate Cancer Working Group 2020, ' Oligometastatic Prostate Cancer: Results of a Dutch Multidisciplinary Consensus Meeting ', European Urology Oncology, vol. 3, no. 2, pp. 231-238 . https://doi.org/10.1016/j.euo.2019.07.010
Background: Oligometastatic prostate cancer (OMPC) is a heterogeneous disease state that is imperfectly understood, and its clinical implications are unclear. Objective: To determine the consensus of a Dutch multidisciplinary expert panel on biologic
Autor:
Emmy Boerrigter, Guillemette E. Benoist, Inge M. van Oort, Gerald W. Verhaegh, Anton F. J. de Haan, Onno van Hooij, Levi Groen, Frank Smit, Irma M. Oving, Pieter de Mol, Tineke J. Smilde, Diederik M. Somford, Paul Hamberg, Vincent O. Dezentjé, Niven Mehra, Nielka P. van Erp, Jack A. Schalken
Publikováno v:
Cancers
Cancers, Vol 13, Iss 6279, p 6279 (2021)
Cancers, 13
Cancers, 13, 24
Cancers; Volume 13; Issue 24; Pages: 6279
Cancers, Vol 13, Iss 6279, p 6279 (2021)
Cancers, 13
Cancers, 13, 24
Cancers; Volume 13; Issue 24; Pages: 6279
Simple Summary Despite the increasing number of treatments for advanced prostate cancer, the evaluation of the added value of each line of treatment on survival outcome is challenging. Therefore, biomarkers to discriminate short-term survivors from l
Autor:
Mette S. van Ramshorst, Aafke H. Honkoop, Vincent O. Dezentjé, Marie-Jeanne T. F. D. Vrancken Peeters, Caroline M.P.W. Mandigers, Sabine C. Linn, Agnes J. van de Wouw, Gabe S. Sonke, I.A.M. Mandjes, Erik van Werkhoven, Anna van der Voort, Jelle Wesseling, Inge Kemper, Laurence J. C. van Warmerdam, Lidwine W. Tick, Irma M. Oving
Publikováno v:
The Lancet Oncology. 19:1630-1640
Summary Background The optimal chemotherapy backbone for dual HER2 blockade in the neoadjuvant setting for early breast cancer is unknown. We investigated whether the addition of anthracyclines would improve pathological complete response compared wi
Autor:
Tineke J. Smilde, Frank Smit, Irma M. Oving, Guillemette E. Benoist, D.M. Somford, O. van Hooij, Gerald W. Verhaegh, P. De Mol, J.A. Schalken, N. P. van Erp, I.M. van Oort, Niven Mehra, Levi Groen, Emmy Boerrigter
Publikováno v:
Molecular Oncology, 15, 9, pp. 2453-2465
Molecular Oncology, 15, 2453-2465
Molecular Oncology
Molecular Oncology, Vol 15, Iss 9, Pp 2453-2465 (2021)
Molecular Oncology, 15, 2453-2465
Molecular Oncology
Molecular Oncology, Vol 15, Iss 9, Pp 2453-2465 (2021)
Circulating RNAs extracted from liquid biopsies represent a promising source of cancer‐ and therapy‐related biomarkers. We screened whole blood from patients with metastatic castration‐resistant prostate cancer (mCRPC) following their first‐l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d7e695322439948eb2df235ab2fbdd5
https://doi.org/10.1002/1878-0261.12933
https://doi.org/10.1002/1878-0261.12933
Autor:
Aafke H. Honkoop, Marie-Jeanne T. F. D. Vrancken Peeters, I.A.M. Mandjes, Caroline M.P.W. Mandigers, Irma M. Oving, Annelie J. Vulink, Lidwine W. Tick, Anna van der Voort, Inge Kemper, GS Sonke, Sabine C. Linn, Agnes J. van de Wouw, Mette S. van Ramshorst, Laurence J. C. van Warmerdam, Erik van Werkhoven, Jelle Wesseling
Publikováno v:
JAMA Oncology. 7:978
Importance Primary analysis of the TRAIN-2 study showed high pathologic complete response rates after neoadjuvant chemotherapy with or without anthracyclines plus dualERBB2(formerlyHER2) blockade. Objective To evaluate 3-year event-free survival (EFS
Autor:
Danny Houtsma, Andre M. Bergman, Suzan Ras van Spijk, Irma M. Oving, Vincent van der Noort, Vincent O. Dezentjé, Paul Hamberg, Kim van der Zande, H. Pieter van den Berg, Milou Busard, Wilbert Zwart, Diederik ten Oever, Metin Tascilar, Aart Beeker, Jeantine M de Feijter
Publikováno v:
Journal of Clinical Oncology. 39:5059-5059
5059 Background: In the OSTRICh trial, poor-prognosis mCRPC patients were randomized between CBZ and ARTA, following progression on docetaxel (DOC) treatment. Methods: The OSTRICh trial is an open label, multicenter, phase IIb study. Patients with po
Autor:
Sabine C. Linn, Gabe S. Sonke, I.A.M. Mandjes, Inge Kemper, Carolien H. Smorenburg, Aafke H. Honkoop, Erik van Werkhoven, Jacqueline M. Stouthard, Irma M. Oving, Mette S. van Ramshorst, Vincent O. Dezentjé
Publikováno v:
The Breast. 29:153-159
Background The addition of pertuzumab to neoadjuvant trastuzumab-based chemotherapy improves pathologic complete response rates in HER2-positive breast cancer. However, increased toxicity has been reported with the addition of pertuzumab, and this ma